Asthma is a long-term inflammatory disease that causes inflammation and narrowing of the airways in the lung. It is characterized by various symptoms such as swelling or inflammation in the airways linings, coughing, shortness of breath, and tightness of chest. Asthma is classified into many different types including allergic asthma, non-allergic asthma, adult onset asthma, exercised induced asthma (that occurs with physical exertion), nocturnal asthma, and occupational asthma. Nocturnal is also known as the nighttime asthma. It is very serious type of asthma therefore, it needs a proper diagnosis and treatment.
Market Dynamics
Increasing launches of nebulizer by key players is expected to propel global asthma therapeutics market growth. For instance, in October 2018, Koninklijke Philips N.V. announced launch of its new mesh nebulizer, InnoSpire Go, in North America. This is used for the treatment of respiratory diseases including asthma. It is portable, hand-held nebulizer system, which is short time treatment. It delivers the medicine in just four minutes. InnoSpire Go designed for both adults and children.
However, product recall is major restraining factor for asthma therapeutics market growth, which is expected to hamper the market growth. For instance, in August 2018, Camber Pharmaceuticals were issued product recall alert from U.S. Food and Drug Administration for its Montelukast Sodium Tablets. These tablets are recalled because Montelukast Sodium Tablet bottles contain wrong medicine (Losartan Potassium Tablet).
Key features of the study:
- This report provides in-depth analysis of the global asthma therapeutics market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global asthma therapeutics market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, GlaxoSmithKline Plc., Philips Healthcare, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sanofi-Aventis SA, CareFusion Corporation, Sunovion Pharmaceuticals, Inc. Merck & Co., Inc., and Roche Diagnostics.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for global asthma therapeutics market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Asthma Therapeutics Market, By Drug Class:
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- Global Asthma Therapeutics By Route of Administration:
- Oral
- Inhalation
- Injection
- Global Asthma Therapeutics market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Asthma Therapeutics market, By Region:
- North America
- By Country:
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
-
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
-
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
-
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
-
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Class
- Corticosteroids
- Beta2-Agonists (Long-Acting and Short-Acting)
- Leukotriene Inhibitors
- Long-Acting Muscarinic Antagonists (LAMA)
- Interleukin Antagonists
- Anti-Immunoglobulin E (IgE) Agents
- Combination Products (Including Beta2 Agonists/Corticosteroids, Beta2 Agonists/Muscarinic Antagonists/Corticosteroids and Others)
- Others
- By Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- GlaxoSmithKline Plc.,*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Philips Healthcare
- AstraZeneca Plc.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim GmbH
- Sanofi-Aventis SA
- CareFusion Corporation
- Sunovion Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Roche Diagnostics.
“*” marked represents similar segmentation in other categories in the respective section.
